Euroopa Liit -
eesti -
EMA (European Medicines Agency)
kisplyx
eisai gmbh - lenvatinibmesülaat - kartsinoom, neerurakk - antineoplastilised ained - kisplyx is indicated for the treatment of adults with advanced renal cell carcinoma (rcc):in combination with pembrolizumab, as first-line treatment (see section 5. in combination with everolimus, following one prior vascular endothelial growth factor (vegf)-targeted therapy.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
alsitek
ab science - masitinib mesilate - amüotroofiline lateraalskleroos - antineoplastilised ained - ravi lateraalskleroosi.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
masipro
ab science - masitinib mesilate - mastotsütoos - antineoplastilised ained - ravi mastocytosis.